Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Partners to Develop Methodologies for Ensuring Quality of Stem Cell Production

By BiotechDaily International staff writers
Posted on 12 Nov 2012
Biotech companies from the United States and Europe have recently announced an agreement to cooperate on the development of methodologies to enable the consistent production of large quantities of stem cells for research and clinical use.

The American company EMD Millipore (Billerica, MA, USA) offers a broad range of innovative products, services, and business relationships in research, development, and production of biotech and pharmaceutical drug therapies. EMD Millipore is the life science division of Merck KGaA, (Darmstadt, Germany).

The other partner to the agreement is Sistemic Ltd. (Glasgow, United Kingdom). Sistemic is a leading provider of microRNA-based problem-solving services and kit-based products. Their extensive suite of tools for the cell therapy community includes SistemQCT, which is used to characterize cells including stem cells with regard to cell identity, purity, potency, and safety as well as monitoring production quality control. In addition, the drug development market is served through a range of products which include SistemTOXT, SistemKBT, and SistemRNAT.

Under terms of the newly announced agreement the companies will jointly develop proprietary monitoring methodology utilizing Sistemic's microRNA marker detection capability to enable consistent growth of stem cells in EMD Millipore's Mobius CellReady platform. Markers developed in the course of this project may also be incorporated into commercially available kits for quality control of stem cells cultures.

"To advance the progress of stem cell products toward clinical use, it is critical to ensure the consistency and quality of large-scale culture systems," said Robert Shaw, commercial director of EMD Millipore's Stem Cell Initiative. "We are excited to be partnering with Sistemic, as the company's leading microRNA-based solutions will help us continue our efforts toward the commercialization of stem cell processing."

"We are delighted to enter this collaborative arrangement with EMD Millipore," said Jim Reid, CEO of Sistemic. "The fact that EMD Millipore has chosen Sistemic as its collaborative partner is yet another validation of our ground-breaking research and ability to develop systems for quality control of stem cells, and other mutually beneficial products and programs."

Related Links:
EMD Millipore
Merck KGaA
Sistemic Ltd.


Channels

Genomics/Proteomics

view channel
Image: The TheraCyte cell encapsulation device (Photo courtesy of TheraCyte, Inc.).

Encapsulated Human-Insulin-Producing Progenitor Cells Cure Diabetes in Mouse Model

A breakthrough system that allows subcutaneous implantation of encapsulated immature pancreatic cells (beta progenitor cells) was shown to produce enough insulin to correct the symptoms of diabetes in a mouse model.... Read more

Drug Discovery

view channel
Image: Chitosan is derived from the shells of shrimp and other sea crustaceans, including Alaskan pink shrimp, pictured here (Photo courtesy of NOAA - [US] National Oceanic and Atmospheric Administration).

Chitosan Treatment Clears the Way for Antibiotics to Eliminate Recurrent Urinary Tract Infections

Recurrent urinary tract infection was successfully resolved in a mouse model by treatment with the exfoliant chitosan followed by a round of antibiotics. Bacterial urinary tract infection (UTI), most... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.